With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

The in silico clinical trials market is poised for rapid growth, driven by the need to reduce traditional trial costs, AI ...

In the spring of 2020, the digital world served as our global lighthouse, providing orientation and connection when the ...

Magic just didn’t do that. When The Walking Dead showed up as a mechanically unique Secret Lair in 2020, it sparked more ...

Anthropic has a new AI model called Mythos. But the company believes that Mythos is way too powerful for humans and hence so ...

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its ...

Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared cardiac AI ...

We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) and Citeline expanded their strategic ...

Conservation levels of gene expression abundance ratios are globally coordinated in cells, and cellular state changes under such biologically relevant stoichiometric constraints are readable as ...